{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:59:59Z","timestamp":1776722399632,"version":"3.51.2"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>Innovative and sustainable sampling strategies for bioanalytical quantification of drugs and metabolites have gained considerable interest. Scavenging can be stratified as a sustainable sampling strategy using residual material because it aligns with the green principles of waste reduction and sampling optimization. Scavenged sampling includes all biological fluids' (eg, blood, liquor, and urine) leftover from standard clinical care. This review elaborates on the past and current landscape of sustainable sampling within therapeutic drug monitoring, with a focus on scavenged sampling.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>In February 2021, 4 databases were searched to assess the literature on the clinical use of innovative and sustainable sampling techniques without applying publication date restrictions. Studies reporting the clinical use of scavenged blood sampling and bridging studies of scavenged sampling and normal blood sampling were eligible for inclusion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Overall, 19 eligible studies concerning scavenged sampling were identified from 1441 records. Scavenged sampling is mainly applied in the pediatric population, although other patient groups may benefit from this strategy. The infrastructure required for scavenged sampling encounters several challenges, including logistic hurdles, storage and handling conditions, and documentation errors. A workflow is proposed with identified opportunities that guide the implementation of scavenged sampling.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This review presents current evidence on the clinical use of scavenged sampling strategies. Scavenged sampling can be a suitable approach for drug quantification to improve dosage regimens, perform pharmacokinetic studies, and explore the value of therapeutic drug monitoring without additional sample collection.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000928","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T18:35:30Z","timestamp":1634754930000},"page":"215-223","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Review of Scavenged Sampling for Sustainable Therapeutic Drug Monitoring: Do More With Less"],"prefix":"10.1097","volume":"44","author":[{"given":"Stef","family":"Schouwenburg","sequence":"first","affiliation":[{"name":"Departments of Hospital Pharmacy and;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin F. J.","family":"van der Klip","sequence":"additional","affiliation":[{"name":"Departments of Hospital Pharmacy and;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim J. L.","family":"Smeets","sequence":"additional","affiliation":[{"name":"Departments of Hospital Pharmacy and;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole G. M.","family":"Hunfeld","sequence":"additional","affiliation":[{"name":"Departments of Hospital Pharmacy and;"},{"name":"Adult Intensive Care, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert B.","family":"Flint","sequence":"additional","affiliation":[{"name":"Departments of Hospital Pharmacy and;"},{"name":"Department of Pediatrics, Division of Neonatology, Erasmus MC\u2014Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, Netherlands; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthijs","family":"de Hoog","sequence":"additional","affiliation":[{"name":"Department of Pediatric Intensive Care, Erasmus MC\u2014Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Endeman","sequence":"additional","affiliation":[{"name":"Adult Intensive Care, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit C. P.","family":"Koch","sequence":"additional","affiliation":[{"name":"Departments of Hospital Pharmacy and;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enno D.","family":"Wildschut","sequence":"additional","affiliation":[{"name":"Department of Pediatric Intensive Care, Erasmus MC\u2014Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Abdulla","sequence":"additional","affiliation":[{"name":"Departments of Hospital Pharmacy and;"},{"name":"Department of Pediatric Intensive Care, Erasmus MC\u2014Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1002\/jcph.1053","article-title":"Innovative study designs optimizing clinical pharmacology research in infants and children","volume":"58","author":"Balevic","year":"2018","journal-title":"J Clin Pharmacol."},{"issue":"suppl 10","key":"R3-20250603","first-page":"S108","article-title":"Optimizing antibiotic drug therapy in pediatrics: current state and future needs","volume":"58","author":"Le","year":"2018","journal-title":"J Clin Pharmacol."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1377\/hlthaff.2020.01103","article-title":"Health care sustainability metrics: building a safer, low-carbon health system","volume":"39","author":"Hensher","year":"2020","journal-title":"Health Aff (Millwood)"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/01.NAJ.0000660032.02514.ec","article-title":"Reducing waste and increasing sustainability in health care settings","volume":"120","author":"Kleber","year":"2020","journal-title":"Am J Nurs."},{"key":"R6-20250603","first-page":"12","article-title":"Sustainable consumption, behaviour change policies and theories of practice","volume":"12","author":"Evans","year":"2012","journal-title":"COLLeGIUM: Stud Across Disciplines Humanities Soc Sci."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/17425255.2016.1178238","article-title":"Is there a role for microsampling in antibiotic pharmacokinetic studies?","volume":"12","author":"Parker","year":"2016","journal-title":"Rev Expert Opin Drug Metab Toxicol"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"350","DOI":"10.2174\/1574884709666140520153308","article-title":"Pharmacokinetic studies in infants using minimal-risk study designs","volume":"9","author":"Autmizguine","year":"2014","journal-title":"Curr Clin Pharmacol."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1128\/AAC.06071-11","article-title":"Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants","volume":"56","author":"Cohen-Wolkowiez","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5195\/jmla.2017.111","article-title":"Reviewing retrieved references for inclusion in systematic reviews using EndNote","volume":"105","author":"Bramer","year":"2017","journal-title":"J Med Libr Assoc."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"e01540","DOI":"10.1128\/AAC.01540-17","article-title":"Development of a novel multipenicillin assay and assessment of the impact of analyte degradation: lessons for scavenged sampling in antimicrobial pharmacokinetic study design","volume":"62","author":"Kipper","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40780-020-00170-y","article-title":"A sensitive method for analyzing fluconazole in extremely small volumes of neonatal serum","volume":"6","author":"Saito","year":"2020","journal-title":"J Pharm Health Care Sci."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1586\/ecp.11.43","article-title":"Innovative clinical trial design for pediatric therapeutics","volume":"4","author":"Laughon","year":"2011","journal-title":"Expert Rev Clin Pharmacol."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1128\/AAC.00569-08","article-title":"Population pharmacokinetics of fluconazole in young infants","volume":"52","author":"Wade","year":"2008","journal-title":"Antimicrob Agents Chemother."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/FTD.0b013e3182587665","article-title":"Population pharmacokinetics of piperacillin using scavenged samples from preterm infants","volume":"34","author":"Cohen-Wolkowiez","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"6572","DOI":"10.1128\/AAC.03568-14","article-title":"Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age","volume":"58","author":"Zhao","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s40262-015-0291-1","article-title":"Pharmacokinetic studies in neonates: the utility of an opportunistic sampling design","volume":"54","author":"Leroux","year":"2015","journal-title":"Clin Pharmacokinet."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/bcp.12710","article-title":"Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease","volume":"80","author":"Zhao","year":"2015","journal-title":"Br J Clin Pharmacol."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1128\/AAC.01045-16","article-title":"A population and developmental pharmacokinetic analysis to evaluate and optimize cefotaxime dosing regimen in neonates and young infants","volume":"60","author":"Leroux","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1128\/AAC.00963-16","article-title":"Population pharmacokinetics of fluconazole in premature infants with birth weights less than 750 grams","volume":"60","author":"Momper","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1128\/AAC.00577-16","article-title":"Development and evaluation of a gentamicin pharmacokinetic model that facilitates opportunistic gentamicin therapeutic drug monitoring in neonates and infants","volume":"60","author":"Germovsek","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10928-018-9576-y","article-title":"A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data","volume":"45","author":"Dallefeld","year":"2018","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"e02448","DOI":"10.1128\/AAC.02448-17","article-title":"Penetration of cefotaxime into cerebrospinal fluid in neonates and young infants","volume":"62","author":"Chen","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"e00075","DOI":"10.1128\/AAC.00075-18","article-title":"Pilot study of model-based dosage individualization of ganciclovir in neonates and young infants with congenital cytomegalovirus infection","volume":"62","author":"Dong","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/cpt.1249","article-title":"Influence of OCT1 ontogeny and genetic variation on morphine disposition in critically ill neonates: lessons from PBPK modeling and clinical study","volume":"105","author":"Hahn","year":"2019","journal-title":"Clin Pharmacol Ther."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"e02336","DOI":"10.1128\/AAC.02336-18","article-title":"Population pharmacokinetics and dosing optimization of amoxicillin in neonates and young infants","volume":"63","author":"Tang","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"R27-20250603","first-page":"S141","article-title":"Population pharmacokinetics and dosing optimization of amoxicillin in chinese infants","volume":"61(S1)","author":"Wu","year":"2020","journal-title":"J Clin Pharmacol."},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3389\/fphar.2020.00014","article-title":"Developmental population pharmacokinetics and dosing optimization of cefepime in neonates and young infants","volume":"11","author":"Zhao","year":"2020","journal-title":"Front Pharmacol."},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/jcph.1773","article-title":"Demonstrating feasibility of an opportunistic sampling approach for pharmacokinetic studies of \u03b2-lactam antibiotics in critically ill children","volume":"61","author":"Tang Girdwood","year":"2021","journal-title":"J Clin Pharmacol."},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/jac\/dkaa071","article-title":"Developmental population pharmacokinetics-pharmacodynamics and dosing optimization of cefoperazone in children","volume":"75","author":"Shi","year":"2020","journal-title":"J Antimicrob Chemother."},{"key":"R31-20250603","first-page":"e01412","article-title":"Optimal dosing of ceftriaxone in infants based on a developmental population pharmacokinetic-pharmacodynamic analysis","volume":"64","author":"Wang","year":"2020","journal-title":"Antimicrob Agents Chemother."},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1128\/AAC.38.12.2817","article-title":"Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children","volume":"38","author":"Reed","year":"1994","journal-title":"Antimicrob Agents Chemother."},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00006454-199205000-00005","article-title":"Pharmacokinetic study of piperacillin in newborns relating to gestational and postnatal age","volume":"11","author":"Kacet","year":"1992","journal-title":"Pediatr Infect Dis J."},{"key":"R35-20250603","first-page":"1161","article-title":"Population pharmacokinetics of favipiravir in patients with COVID-19. CPT pharmacometrics syst pharmacol","volume":"10","author":"Irie","year":"2021"},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/cpt.2194","article-title":"Biomarker-guided individualization of antibiotic therapy","volume":"110","author":"Aulin","year":"2021","journal-title":"Clin Pharmacol Ther."},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/1087057103252618","article-title":"The effect of freeze\/thaw cycles on the stability of compounds in DMSO","volume":"8","author":"Kozikowski","year":"2003","journal-title":"J Biomol Screen."},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1515\/cclm-2012-0447","article-title":"The impact on costs and efficiency of reducing the number of collected tubes","volume":"51","author":"Hobson","year":"2013","journal-title":"Clin Chem Lab Med."},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/FTD.0000000000000904","article-title":"Theoretical performance of nonlinear mixed-effect models incorporating saliva as an alternative sampling matrix for therapeutic drug monitoring in pediatrics: a simulation study","volume":"43","author":"Kruizinga","year":"2021","journal-title":"Ther Drug Monit."},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1208\/s12248-017-0161-x","article-title":"Pharmacogenomic biomarkers for improved drug therapy\u2014recent progress and future developments","volume":"20","author":"Lauschke","year":"2017","journal-title":"AAPS J."},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1073\/pnas.1613458114","article-title":"Real-time measurement of small molecules directly in awake, ambulatory animals","volume":"114","author":"Arroyo-Curr\u00e1s","year":"2017","journal-title":"Proc Natl Acad Sci U S A."},{"key":"R43-20250603","first-page":"56","article-title":"Pharmacodynamics of immune response biomarkers of interest for evaluation of treatment effects in bacterial infections","volume":"106059","author":"Thorsted","year":"2020","journal-title":"Int J Antimicrob Agents."},{"key":"R44-20250603","first-page":"59","article-title":"Clinical utility and measurement of procalcitonin","volume":"38","author":"Samsudin","year":"2017","journal-title":"Clin Biochem Rev."},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"613422","DOI":"10.3389\/fimmu.2021.613422","article-title":"Interleukin-6 is a biomarker for the development of fatal severe acute respiratory syndrome coronavirus 2 pneumonia","volume":"12","author":"Santa Cruz","year":"2021","journal-title":"Front Immunol."},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13054-020-03423-2","article-title":"Association of inflammatory biomarkers with subsequent clinical course in suspected late onset sepsis in preterm neonates","volume":"25","author":"Kurul","year":"2021","journal-title":"Crit Care."},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"From therapeutic drug monitoring to model-informed precision dosing for antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin Pharmacol Ther."},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1515\/cclm-2018-1323","article-title":"Advantages and limitations of total laboratory automation: a personal overview","volume":"57","author":"Giuseppe","year":"2019","journal-title":"Clin Chem Lab Med."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000928","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:26:58Z","timestamp":1748971618000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000928","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,18]]}}}